Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva has faced a tough couple of years, to put it mildly.

Teva: Generidiculous 2.0

Teva (TEVA) launches generic version of Mylan's (MYL) popular EpiPen Jr allergy treatment at a price of $300 for a pack of two.

Teva Launches Generic Version of Mylan's EpiPen for KIds

Shares of Teva Pharmaceutical Industries TEVA, +4.47% rose 3% in premarket trade Wednesday after The Lancet published results from a late-stage study showing that patients on the company's migraine treatment Ajovy, also known as fremanezumab, experienced a significant reduction in migraine days when compared to patients on placebo.

Shares of Teva up 3% on positive migraine trial

Wells Fargo

These three stocks from Berkshire Hathaway’s portfolio are too cheap to ignore.

3 Warren Buffett  Stocks to Buy Right Now

Teva Pharmaceutical Industries Ltd. TEVA, +4.68% said Tuesday its FDA-approved generic version of the EpiPen is available in the U.S.

Teva says FDA-approved generic EpiPen is now available in the U.S. for $300 for a 2-pack

Let's see if Teva Pharmaceutical (TEVA) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Pick Teva Pharmaceutical (TEVA) Now?

Shares of Teva Pharmaceutical Industries Ltd. TEVA, -10.23% tumbled 9.7% toward a 20-year low, after Moody's Investors Service revised its outlook on the drug maker's already "junk" credit rating to negative from stable.

Teva's stock tumbles toward 20-year low; Moody's turns negative on drugmaker's 'junk'-rated debt

Opioid-related lawsuits is a significant threat for Teva, but it can be overcome.

Teva: Maximum Pessimism

Teva Pharmaceutical (TEVA) posts better-than-expected results. However, earnings and sales decline year over year.

Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down

Teva Pharmaceutical Industries Limited (TEVA) CEO Kare Schultz on Q2 2019 Results - Earnings Call Transcript

Teva Pharmaceutical (TEVA) posts better-than-expected results. Shares rise in pre-market trading.

Teva (TEVA) Beats Q2 Earnings & Sales Estimates, Shares Rise

Teva Pharmaceutical Indus (NYSE: TEVA) reported second-quarter earnings of 60 cents per share, which beat the analyst consensus estimate of 57 cents by 5.26%.

Teva Reports Q2 Earnings Beat, Reaffirms Guidance

Shares of Teva Pharmaceutical Industries Ltd. TEVA, -9.83% jumped 4.1% in premarket trading Wednesday, after the branded and generic drugmaker reported second-quarter results that beat expectations, with Copaxone sales falling less than projected.

Teva's stock jumps off 20-year low after earnings beat expectations; CFO to step down

Chesapeake Energy

GreenSky

Despite a nice bounce for the market, these stocks didn't join in the rally.

Why Chesapeake Energy, Teva Pharmaceutical Industries, and GreenSky Slumped Today

A confluence of bad news has sunk the stock to a 20-year low.

Here's What's Pushing Teva Pharmaceutical Industries Stock Even Lower Today

Beyond Meat

PaySign Inc

Sogou

Take-Two Interactive Software

Teva, Take-Two, Beyond Meat, PaySign and Sogou were our top stock trades on Tuesday. Here's how to trade them.

5 Top Stock Trades for Wednesday: TEVA, TTWO, BYND

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q2.

Will Cost Control Help Teva (TEVA) Beat on Q2 Earnings?

Now that Pfizer (NYSE:PFE)'s Upjohn and Mylan (NASDAQ:MYL) are combining in a new spinoff, it looks like Teva (NYSE:TEVA) could be next.

After Mylan Gets Acquired, Could Teva Be Next?

2018 proved to be just a pause in the streak of bad news that keep hitting TEVA.

Teva, Mylan: Desperate Times Call For Desperate Measures

I have had Teva (NYSE:TEVA), an Israel-based drugmaker, on my stock watchlist for a long time.

Value Idea Contest: Is Teva Pharmaceutical Industries Ltd. a Buffett bargain?

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) shares are down 66.1% in the past year on fears about the negative impact of opioid litigation.

Large Option Trader Makes Aggressive Bearish Play On Teva

Amneal Pharmaceuticals

Endo International

Mylan

Pharmaceutical stocks Teva Pharmaceutical, Mylan, Endo and Amneal Pharmaceuticals may have to pay $8.5 billion in litigation costs surrounding the opioid epidemic, an analyst said Monday.

These Pharmas Could Be On The Hook For Billions In The Opioid Epidemic

Bernard Horn Comments on Teva Pharmaceutical

Abbott Labs

SPDR Gold Trust

Invitae

Tesla

Tesla, Teva, Abbott Labs, Invitae and the gold ETF were are top stock trades on Wednesday. Let's look at the setups heading into Thursday.

5 Top Stock Trades for Thursday (July 18)

Mallinckrodt PLC

These drug developers are all valued at less than four times this year's projected earnings per share.

News for Teva Pharmaceutical Stock (TEVA)